Search

REVOLUTION Medicines Inc

Chiusa

SettoreSettore sanitario

202.62 -0.95

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

199.66

Massimo

206.37

Metriche Chiave

By Trading Economics

Entrata

-644M

-1.1B

EPS

-2.34

Dipendenti

883

EBITDA

-184M

-621M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+23.69% upside

Dividendi

By Acuity

Utili prossimi

4 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

6.2B

45B

Apertura precedente

203.57

Chiusura precedente

202.62

Notizie sul Sentiment di mercato

By Acuity

76%

24%

308 / 339 Classifica in Healthcare

REVOLUTION Medicines Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 set 2026, 20:08 UTC

Revolution Medicines Inc shares are higher during Friday's session, despite earlier pulling back from an intraday high. No specific news was identified for the movement.

3 set 2026, 19:16 UTC

News

Revolution Medicines Inc shares are higher after positive Phase 1/2 trial results for RASONQUE in advanced RAS mutant non-small cell lung cancer were published.

2 set 2026, 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

1 set 2026, 23:06 UTC

Revolution Medicines Inc shares are higher in after-market trading, maintaining a stable performance since Tuesday's close despite earlier session volatility.

31 ago 2026, 20:07 UTC

Correlated Moves
News

Revolution Medicines Inc shares are lower amid broader market pressures and concerns from the Jackson Hole Economic Symposium regarding inflation and monetary policy tightening.

28 ago 2026, 20:02 UTC

Social Media
News

Revolution Medicines shares are lower amid significant selling pressure, despite recent price target increases by UBS and others for its drug RASONQUE.

27 ago 2026, 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

26 ago 2026, 23:21 UTC

News
Social Media

Oppenheimer raised Revolution Medicines' price target to $260, citing FDA approval of RASONQUE for advanced pancreatic cancer, as shares trade higher in after-market hours.

25 ago 2026, 20:07 UTC

News

Revolution Medicines Inc received a "Moderate Buy" rating from brokerages. Needham raised its price target to $240, while shares are trading roughly flat.

24 ago 2026, 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21 ago 2026, 19:46 UTC

News

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20 ago 2026, 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19 ago 2026, 19:46 UTC

News

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17 ago 2026, 19:51 UTC

Social Media

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13 ago 2026, 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12 ago 2026, 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11 ago 2026, 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10 ago 2026, 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7 ago 2026, 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6 ago 2026, 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5 ago 2026, 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4 ago 2026, 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3 ago 2026, 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 lug 2026, 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 lug 2026, 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 lug 2026, 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 lug 2026, 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 lug 2026, 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 lug 2026, 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 lug 2026, 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

Confronto tra pari

Modifica del prezzo

REVOLUTION Medicines Inc Previsione

Obiettivo di Prezzo

By TipRanks

23.69% in crescita

Previsioni per 12 mesi

Media 252.053 USD  23.69%

Alto 320 USD

Basso 179 USD

Basato su 21 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

21 ratings

20

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

308 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat